Lista de obras -

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

artículo científico publicado en 2016

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

scientific article published on 16 October 2019

Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows

scientific article published on 27 February 2019

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

artículo científico publicado en 2014

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

artículo científico publicado en 2013

Are SOFT and TEXT results practice changing and how?

artículo científico publicado en 2016

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

artículo científico publicado en 2015

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

artículo científico publicado en 2012

Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.

artículo científico publicado en 2017

Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop

artículo científico publicado en 2018

Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations

artículo científico publicado en 2014

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

artículo científico publicado en 2010

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

artículo científico publicado en 2010

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

artículo científico publicado en 2020

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

artículo científico publicado en 2017

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

artículo científico publicado en 2015

Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial

artículo científico publicado en 2020

Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series

artículo científico publicado en 2014

Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

artículo científico publicado en 2014

First international consensus guidelines for breast cancer in young women (BCY1).

artículo científico

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

artículo científico publicado en 2016

Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93.

artículo científico publicado en 2013

International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer

artículo científico publicado en 2013

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

artículo científico publicado en 2010

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

artículo científico publicado en 2009

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

artículo científico publicado en 2019

Luminal Metastatic Breast Cancer

artículo científico publicado en 2019

Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer

artículo científico publicado en 2017

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

artículo científico publicado en 2015

Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?

scientific article published on 08 October 2020

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

artículo científico publicado en 2020

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

artículo científico publicado en 2015

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

artículo científico publicado en 2015

Pregnancy after breast cancer: if you wish, ma’am ⬇️

artículo científico publicado el 23 de junio de 2011

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

artículo científico publicado en 2019

Second international consensus guidelines for breast cancer in young women (BCY2).

artículo científico publicado en 2016

Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

artículo científico

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

artículo científico publicado en 2018

The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer

artículo científico

Time for more optimism in metastatic breast cancer?

artículo científico publicado en 2013

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care

artículo científico publicado en 2016

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

artículo científico publicado en 2017

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

scientific article published on 09 April 2020

Lista de obras de

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.

Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT

Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptor-Positive Early Breast Cancer: Lights and Shadows

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer

Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.

Are SOFT and TEXT results practice changing and how?

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial

CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial

Cancer Predisposition Cascade Screening for Hereditary Breast/Ovarian Cancer and Lynch Syndromes in Switzerland: Study Protocol.

Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop

Challenges in managing genetic cancer risk: a long-term qualitative study of unaffected women carrying BRCA1/BRCA2 mutations

Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial

Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial

Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trial

Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series

Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

First international consensus guidelines for breast cancer in young women (BCY1).

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial

Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93.

International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer

International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Luminal Metastatic Breast Cancer

Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.

Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Pregnancy after breast cancer: if you wish, ma’am ⬇️

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

Second international consensus guidelines for breast cancer in young women (BCY2).

Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement.

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

The European Society of Breast Cancer Specialists recommendations for the management of young women with breast cancer

Time for more optimism in metastatic breast cancer?

Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy